Overexpression of PLCE1 in kazakh esophageal squamous cell carcinoma: Implications in cancer metastasis and aggressiveness

APMIS

Volumn 121, Issue 10, 2013, Pages 908-918

  Chen, Yun Zhao ^a,b   Cui, Xiao Bin ^a,b   Hu, Jian Ming ^b   Zhang, Wen Jie ^a,b   Li, Shu Gang ^b   Yang, Lan ^b   Shen, Xi Hua ^b   Liu, Chun Xia ^b   Pan, Qing Fang ^b   Yu, Shi Ying ^a   Yuan, Xiang Lin ^a   Yang, Lei ^c   Gu, Wen Yi ^d,e   Chen, Jie Zhong ^d   Wang, Li Dong ^f   Li, Feng ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHIHEZI UNIVERSITY   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

^d QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f ZHENGZHOU UNIVERSITY   (China)

Author keywords

Aggressiveness; Cancer metastasis; Kazakh esophageal squamous cell carcinoma; phospholipase C epsilon 1 (PLCE1)

Indexed keywords

MESSENGER RNA; PHOSPHOLIPASE C; PHOSPHOLIPASE C EPSILON 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYTOPLASM; DISEASE SEVERITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ETHNICITY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; POPULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR INVASION;

AGGRESSIVENESS; CANCER METASTASIS; KAZAKH ESOPHAGEAL SQUAMOUS CELL CARCINOMA; PHOSPHOLIPASE C EPSILON 1 (PLCE1);

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHINA; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; KAZAKHSTAN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHOINOSITIDE PHOSPHOLIPASE C; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884712035     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12095     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Li L, Lu F, Zhang S. Analyses of variation trend and short-term detection of Chinese malignant tumor mortality during twenty years. Zhonghua Zhong Liu Za Zhi 1997;19:3-9.
3. Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 2005;54:187-92.
4. Lu JB, Yang WX, Liu JM, Li YS, Qin YM. Trends in morbidity and mortality for oesophageal cancer in Linxian County, 1959-1983. Int J Cancer 1985;36:643-5.
5. Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 2011;43:679-84.
6. Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 2010;42:759-63.
7. Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 2010;42:764-7.
8. Kelley GG, Reks SE, Ondrako JM, Smrcka AV. Phospholipase C(epsilon): a novel Ras effector. EMBO J 2001;20:743-54.
9. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 2001;70:281-312.
10. Lopez I, Mak EC, Ding J, Hamm HE, Lomasney JW. A novel bifunctional phospholipase c that is regulated by Galpha 12 and stimulates the Ras/mitogen-activated protein kinase pathway. J Biol Chem 2001;276:2758-65.
11. Wing MR, Bourdon DM, Harden TK. PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv 2003;3:273-80.
12. Bunney TD, Baxendale RW, Katan M. Regulatory links between PLC enzymes and Ras superfamily GTPases: signalling via PLCepsilon. Adv Enzyme Regul 2009;49:54-8.
13. Bai Y, Edamatsu H, Maeda S, Saito H, Suzuki N, Satoh T, et al. Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res 2004;64:8808-10.
14. Oka M, Edamatsu H, Kunisada M, Hu L, Takenaka N, Dien S, et al. Enhancement of ultraviolet B-induced skin tumor development in phospholipase Cepsilon-knockout mice is associated with decreased cell death. Carcinogenesis 2010;31:1897-902.
15. Peng Z, Zhang F, Zhou C, Ling Y, Bai S, Liu W, et al. Genome-wide search for loss of heterozygosity in Chinese patients with sporadic colorectal cancer. Int J Gastrointest Cancer 2003;34:39-48.
16. Wang X, Zbou C, Qiu G, Fan J, Tang H, Peng Z. Screening of new tumor suppressor genes in sporadic colorectal cancer patients. Hepatogastroenterology 2008;55:2039-44.
17. Wang X, Zhou C, Qiu G, Yang Y, Yan D, Xing T, et al. Phospholipase C epsilon plays a suppressive role in incidence of colorectal cancer. Med Oncol 2011;29:1051-8.
18. Ling Y, Chunli L, Xiaohou W, Qiaoling Z. Involvement of the PLCepsilon/PKCalpha pathway in human BIU-87 bladder cancer cell proliferation. Cell Biol Int 2011;35:1031-6.
19. Ou L, Guo Y, Luo C, Wu X, Zhao Y, Cai X. RNA interference suppressing PLCE1 gene expression decreases invasive power of human bladder cancer T24 cell line. Cancer Genet Cytogenet 2010;200:110-9.
20. Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2 + signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem 2006;281:14026-40.
21. Ma H, Wang LE, Liu Z, Sturgis EM, Wei Q. Association between novel PLCE1 variants identified in published esophageal cancer genome-wide association studies and risk of squamous cell carcinoma of the head and neck. BMC Cancer 2011;11:258.
22. Hu H, Yang J, Sun Y, Yang Y, Qian J, Jin L, et al. Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a Case-Control study in Eastern Chinese populations. Ann Surg Oncol 2012;19:2403-10.
23. Harden TK, Sondek J. Regulation of phospholipase C isozymes by ras superfamily GTPases. Annu Rev Pharmacol Toxicol 2006;46:355-79.
24. Ada-Nguema AS, Xenias H, Hofman JM, Wiggins CH, Sheetz MP, Keely PJ. The small GTPase R-Ras regulates organization of actin and drives membrane protrusions through the activity of PLCepsilon. J Cell Sci 2006;119:1307-19.
25. Shibatohge M, Kariya K, Liao Y, Hu CD, Watari Y, Goshima M, et al. Identification of PLC210, a Caenorhabditis elegans phospholipase C, as a putative effector of Ras. J Biol Chem 1998;273:6218-22.
26. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-35.
27. Cheung WY, Liu G. Genetic variations in esophageal cancer risk and prognosis. Gastroenterol Clin North Am 2009;38:75-91, viii.
28. Gbadegesin R, Hinkes BG, Hoskins BE, Vlangos CN, Heeringa SF, Liu J, et al. Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant 2008;23:1291-7.
29. Li M, Edamatsu H, Kitazawa R, Kitazawa S, Kataoka T. Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis. Carcinogenesis 2009;30:1424-32.
30. Johmura Y, Osada S, Nishizuka M, Imagawa M. FAD24, a regulator of adipogenesis, is required for the regulation of DNA replication in cell proliferation. Biol Pharm Bull 2008;31:1092-5.
31. Danielsen SA, Cekaite L, Agesen TH, Sveen A, Nesbakken A, Thiis-Evensen E, et al. Phospholipase C isozymes are deregulated in colorectal cancer-insights gained from gene set enrichment analysis of the transcriptome. PLoS ONE 2011;6:e24419.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
33. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.